Answers are grounded in this paper and cite their sources.
Thyroid hormones are of interest because of their ability to reduce serum cholesterol and triglycerides and their ability to reduce adiposity. Unfortunately, naturally occurring thyroid hormones, such as T3 (thyroid hormone) or T4 (thyroxine), cannot be used to treat obesity or hyperlipidemia in euthyroid subjects owing to cardiovascular complications. The two primary thyroid hormone receptor (TR) subtypes, TR± and TR², are ubiquitously expressed, with TR± predominance in heart, bone and brain and TR² predominance in the liver and pituitary. This selective expression and perhaps selective TR function makes TR² agonists potentially useful for treating obesity and hyperlipidemia without cardiac effects. TR²-selective activation shows promise as there is a therapeutic window in which cholesterol is lowered and metabolic rate is increased without cardiac acceleration. This was shown in TR±-/- mice and for the TR²-selective agonists GC-1 and KB-141. This should translate into antiobesity, lipid-lowering and potentially antidiabetic effects for TR² agonists.
No takes yet. Share an insight, caveat, or question.
Grover et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: